Lhasa India Symposium 2026
Science, strategy and regulatory best practice
Join Lhasa experts and industry speakers in Hyderabad on 29th October for a day of practical scientific insight, industry case studies and interactive discussion on the decisions that shape pharmaceutical quality and safety.
Explore the connections between pre-formulation, forced degradation, ICH M7, genetic toxicology, extractables and leachables, ICH Q3E, purge and acceptable intakes, with perspectives from Lhasa and pharmaceutical industry specialists.
Why attend?
Hear industry perspectives
Explore practical case studies and evolving quality and safety expectations from speakers across the pharmaceutical industry.
Work through real decisions
Take part in an ICH M7 workshop and an E&L roundtable, with opportunities to question and compare approaches.
Connect with specialists
Exchange ideas with Lhasa scientists and peers across toxicology, CMC, regulatory affairs and pharmaceutical development.
A connected risk assessment workflow
From drug substance composition and degradation to genotoxicity, E&L and exposure-based decisions, the programme follows the evidence through key pharmaceutical quality and safety challenges.
See where in silico methods, curated data, read-across and expert scientific interpretation can strengthen the rationale behind an assessment.
Explore the full agenda
Thursday 29 October 2026 | Radisson Blu Plaza, Banjara Hills, Hyderabad
Select a session to view talk times, speakers and programme details.
Registration and openingWelcome to the symposium
09:10
2026 landscape in India: why quality-based decisions matter now
Dr Adrian Fowkes · Lhasa Limited
Session 01Composition of your Drug Substance and Drug Product
09:30
In silico pre-formulation studies: how Zeneth (Lhasa Limited) supports quality drug substances
Pavlos Dimitriou · Lhasa Limited
09:50
Pitfalls in submission for forced degradation studies
Dr Krishnam Raju Chintapali · Natco
10:20
ICH Q3 to M7: Where quality flows into safety
Mitali Kamat · Lhasa Limited
10:25
Coffee and demonstration break
Session 02Genotoxicity Safety Decision Support: ICH M7, S1 & S2
10:40
Genotoxicity: ICH M7 Case Study
Dr Ravichandra Bhadravathi Vedamurthy · Amneal Pharmaceuticals
11:00
ICH M7 workshop
Interactive session with materials provided · Mitali Kamat, Lhasa Limited
Session 03Extractables & Leachables (E&L)
13:20
E&L risk assessment: confident decisions using a multi-faceted read-across approach
Jessica Halliday · Lhasa Limited
13:40
ICH Q3E applications in industry
Dr Ashutosh Ratnakar Joshi · Dr Reddy’s
14:00
Regulatory expectations on the implementation of ICH Q3E Remote speaker
Dr Patricia Parris · Pfizer
14:20
E&Ls roundtable
Interactive session · Chair: Jessica Halliday, Lhasa Limited · Panellists: Dr Ashutosh Ratnakar Joshi · Dr Reddy’s, Dr Patricia Parris · Pfizer and Dr Adrian Fowkes · Lhasa Limited
14:40
Coffee and demonstration break
Session 04PMI Quality, Purge & Acceptable Intakes
15:20
Purge: a lens into exposure quality as part of ICH M7 risk assessment
Amber Carr · Lhasa Limited
15:40
Purge case study applications in industry Remote speaker
Dr Andrew Teasdale · AstraZeneca
16:10
Read-across for nitrosamine impurities: from surrogate selection to weight of evidence Remote speaker
Dr Ben Thornton · Consult Lhasa
Closing remarks and networkingContinue the conversation
16:45
Symposium summary
Dr Adrian Fowkes · Lhasa Limited
Join us in Hyderabad
Explore the programme, meet industry peers and secure your place using the registration options below.
